Get ready for ASH
Will Bristol-Myers Squibb be a player in CAR-T? Can CRISPR treat cancer? And could gene therapy cure hemophilia B?
We’re going to learn more on all of the above this weekend at the American Society of Hematology meeting, which begins Saturday in Orlando. Among the big draws are data on JCAR17, a CAR-T invented by Juno Therapeutics and acquired by Celgene that is now key to Bristol-Myers’s future in the space. We’ll also see data from Tmunity, a company using CRISPR to craft cancer-killing cells, and an update from Uniqure on what could be the first one-time treatment for hemophilia B.
STAT is sending Adam Feuerstein to the Magic Kingdom to cover all that and more, and you can read his reportage by signing up for our free ASH newsletter.
We’re going to learn more on all of the above this weekend at the American Society of Hematology meeting, which begins Saturday in Orlando. Among the big draws are data on JCAR17, a CAR-T invented by Juno Therapeutics and acquired by Celgene that is now key to Bristol-Myers’s future in the space. We’ll also see data from Tmunity, a company using CRISPR to craft cancer-killing cells, and an update from Uniqure on what could be the first one-time treatment for hemophilia B.
STAT is sending Adam Feuerstein to the Magic Kingdom to cover all that and more, and you can read his reportage by signing up for our free ASH newsletter.
No hay comentarios:
Publicar un comentario